Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Axogen Initiates Rolling Submission Process With FDA For Biologics License Application For Licensure Of Avance Nerve Graft

Author: Benzinga Newsdesk | May 16, 2024 07:34am

The company anticipates the BLA filing to be completed in the third quarter of 2024 and believe the procedural timelines for review combined with the rolling submission process will allow for approval around mid-2025.

Posted In: AXGN